| Open Document File Size: 1,00 MBShare Result on Facebook
City Reference / Princeton / / Company Novo Nordisk Inc. / / Country United States / / Event FDA Phase / / Facility College Road West / / / IndustryTerm neck imaging / healthcare providers / / MedicalCondition thyroid nodules / dose-dependent and treatment-duration-dependent thyroid C-cell tumors / thyroid C-cell tumors / vomiting / medullary thyroid tumors / medullary thyroid cancer / diabetes mellitus / state cancer / Multiple Endocrine Neoplasia syndrome type / pancreatitis / acute pancreatitis / persistent severe abdominal pain / medullary thyroid carcinoma / / Organization Food and Drug Administration / FDA / / Person MARY H PARKS / Alan C. Moses / / / Position nurse / representative / Global Chief Medical Officer / M.D. Global Chief Medical Officer / / Product VICTOZA® / / ProvinceOrState New Jersey / / PublishedMedium the Medication Guide / / Technology http / / URL http /
SocialTag |
APPENDIX A: REMS Initial REMS approval: [removed]Most recent modification: [removed]NDA[removed]VICTOZA® (liraglutide [rDNA origin] injection) Novo Nordisk Inc.